etoricoxib / Generic mfg. - LARVOL DELTA

AN ATYPICAL PRESENTATION OF PSEUDOMEMBRANOUS ESOPHAGITIS IN HSV INFECTION (UEGW 2026) - "Drug history included etoricoxib 4 weeks prior and alendronic acid since 2020. She received oral prednisolone 15mg daily for joint pain but developed melena on day 4...She received 3 weeks of oral Valganciclovir with resolution of esophagitis at repeat OGD 3 months later.This case is notable for two atypical features of HSV infection: pseudomembranous endoscopic appearance and presentation with melena after transient immunosuppression...Tissue biopsy remains essential for accurate diagnosis as endoscopic appearance alone is insufficient. Prompt HSV identification guides timely antiviral therapy."

Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Disorders • Herpes Simplex • Hypotension • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis

Fixed drug eruption due to etoricoxib confirmed by lesional patch testing (EADV 2026) - No abstract available

Contact Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Design, development, and optimisation of an amorphous solid dispersion-based etoricoxib bigel for targeted topical anti-inflammatory drug delivery. (PubMed, Inflammopharmacology) - "The developed bigel formulation exhibited favourable physicochemical and biopharmaceutical properties, indicating strong potential as an effective topical delivery system for the management of pain and inflammation."

Journal • Inflammation • Pain

An Open-Label, Single-Arm Exploratory Study Evaluating an IL-1 Inhibitor Combined with Etoricoxib as First-Line Therapy in Patients with Acute Gouty Arthritis (ChiCTR) - P4 | N=53 | Not yet recruiting | Sponsor: The First Hospital of Jilin University; The First Hospital of Jilin University

New P4 trial • Gout • Immunology • Inflammatory Arthritis • Rheumatology

Extensive oral stomatitis triggered by etoricoxib in an elderly patient: a case report (EADV 2026) - No abstract available

Case report • Clinical • Dental Disorders • Stomatitis

Etoricoxib-Betamethasone Combination Attenuates Inflammatory Nociception and Edema in Adjuvant-Induced Arthritis via Cytokine and Macrophage Axis Modulation. (PubMed, Pharmaceuticals (Basel)) - " Male Wistar rats (n = 10/group) were allocated to seven groups: Intact, AIA disease control, indomethacin 5 mg/kg, etoricoxib 8 mg/kg, betamethasone 0.022 mg/kg, low-dose combination (4 + 0.011 mg/kg), and full-dose combination (8 + 0.022 mg/kg), administered orally once daily from Days 4 to 28. Biomarker shifts indicated attenuated prostaglandin signaling and a pro-resolving cytokine balance. These findings support the further evaluation of etoricoxib-betamethasone co-therapy for acute inflammatory conditions."

Journal • Immunology • Rheumatology

Safety assessment for ibuprofen using disproportionality analysis: a decade of data from the Romanian national pharmacovigilance system. (PubMed, Front Pharmacol) - "However, the disproportionality analysis, limited by the relatively small number of reports, suggests a higher disproportional reporting of gastrointestinal disorders for ibuprofen than for etoricoxib (ROR 4.74; 95% CI 1.72-13.03). In contrast, a lower disproportional reporting skin and soft tissue ADRs related to ibuprofen, compared with diclofenac (ROR 0.32; 95% CI 0.11-0.95) and celecoxib (ROR 0.17; 95% CI 0.05-0.54), was observed...These findings contribute to a better understanding of ibuprofen safety patterns in routine clinical practice in Romania. The results should be interpreted in the context of inherent limitations, such as underreporting of adverse reactions and the difficulty in establishing causality, particularly for patient-reported cases, which may introduce a higher degree of subjectivity."

Adverse events • Journal • Gastroenterology • Gastrointestinal Disorder • Pain

Comparative Bioavailability of a Fixed-Dose Combination of Etoricoxib and Betamethasone in Healthy Volunteers. (PubMed, Clin Pharmacol Drug Dev) - "Two non-serious adverse events were reported. Results demonstrated that the pharmacokinetic profile and bioavailability of the etoricoxib/betamethasone FDC were comparable to those of reference formulations, with no evidence of pharmacokinetic interactions."

Clinical • Journal

Prospective Real-World Assessment of Pain Relief with Injection-Based Delivery of Etoricoxib (RAPID Study). (PubMed, Drugs Real World Outcomes) - "IM etoricoxib was associated with rapid and sustained pain reduction and demonstrated a favorable tolerability profile across a range of acute pain conditions in Indian clinical practice."

Journal • Real-world evidence • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Intravenous Zoledronic Acid for Bone Pain Relief in Cancer Patients with Bone Metastasis Receiving Low Dose Opioids and Nsaids: A Randomized Controlled Study. (PubMed, J Pain Palliat Care Pharmacother) - "Patients were randomized into two groups (35 each), Group Z received ZA 4 mg intravenously (every 4 wk) along with low-dose morphine 5 mg every 4 h and tablet etoricoxib 60 mg twice daily and Group P received tab morphine 5 mg every 4 h and tab etoricoxib 60 mg twice daily. Patients receiving intravenous ZA demonstrated significantly greater reductions in pain severity and fewer skeletal-related events than Group P (p < 0.05). No serious drug-related adverse effects were noted."

Journal • Endocrine Disorders • Kidney Cancer • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Pain • Palliative care • Renal Cell Carcinoma • Solid Tumor

Effectiveness of etoricoxib on bone microarchitecture in PHO patients: A 12-month longitudinal study assessed by HR-pQCT. (PubMed, Bone) - "Our findings indicated that 12 months of Etoricoxib treatment improved bone microstructure in PHO patients and highlighted differential treatment responses between different genotypes, which might optimize treatment strategies for PHO patients."

Journal • Observational data • Genetic Disorders

Selective COX-2 inhibitors for short-term musculoskeletal pain in inflammatory bowel disease in remission: a narrative review. (PubMed, BMJ Open Gastroenterol) - "Clinical trials and clinical studies evaluating celecoxib, etoricoxib or rofecoxib in patients with IBD and musculoskeletal/rheumatological symptoms were considered when gastrointestinal (GI) outcomes were reported. Overall, the strongest available evidence supports cautious short-term use of selective COX-2 inhibitors in selected patients with IBD in remission when anti-inflammatory analgesia is required. Given the small evidence base and limited follow-up, treatment should be time-limited, use the lowest effective dose and include clinical monitoring."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Rheumatology • Ulcerative Colitis

Axial gout diagnosed by dual-energy CT in a young normouricaemic man with recurrent nephrolithiasis: a case-based review. (PubMed, Rheumatol Int) - "The patient was treated with etoricoxib (60 mg daily) and febuxostat (20 mg daily). A systematic literature review of 58 eligible articles revealed that the lumbar spine was most frequently involved (≈ 60%), DECT sensitivity ranged from 78% to 100%, and 77.5% of historically reported cases required surgical diagnosis, underscoring the underrecognition of axial gout in non-surgical settings. This case‑based review highlights that axial gout should be considered in young non‑hyperuricaemic patients with persistent axial pain, and that DECT is a valuable non‑invasive diagnostic tool when interpreted alongside clinical and laboratory features."

Journal • Review • Back Pain • CNS Disorders • Gout • Inflammatory Arthritis • Lumbar Back Pain • Musculoskeletal Pain • Nephrology • Pain • Renal Calculi • Rheumatology

Efficiency of NSAIDs in preventing prosthetic joint infections (PJIs): inhibition of Staphylococcus aureus biofilms by etoricoxib through down regulation of bacterial adhesion genes. (PubMed, Arch Microbiol) - "The killing-kinetics of etoricoxib was observed at 2 h and the drug showed synergistic effect along with ampicillin and tetracycline, reducing the MIC by 4-fold. Moreover, etoricoxib treatment caused S. aureus cell damage resulting in cell death and was noticed through scanning electron microscope (SEM) analysis. Thus, as etoricoxib was effective in eliminating and preventing biofilms and the authors recommend further in vitro and in vivo studies to explore the possibility for new therapeutic option for implant-associated infections."

Journal • Infectious Disease

Decoding the Haematological Enigma: Insights from Primary Hypertrophic Osteoarthropathy Case Studies. (PubMed, Indian J Hematol Blood Transfus) - "Although etoricoxib, steroids show therapeutic promise. Further extensive research is necessary to establish their efficacy, safety."

Journal • Fatigue • Hematological Disorders • Musculoskeletal Pain • Pediatrics

Case Report: Rapid improvement with upadacitinib in a case of paradoxical skin lesions associated with SAPHO syndrome. (PubMed, Front Immunol) - "Conventional therapy with etoricoxib and methotrexate improved musculoskeletal symptoms but failed to resolve skin lesions, while adalimumab treatment led to progressive worsening of cutaneous manifestations. Following a switch to upadacitinib (15 mg once daily), rapid improvement of skin lesions and sustained control of musculoskeletal symptoms were achieved without adverse events. This case suggests that Janus kinase inhibition may represent a therapeutic option for TNF-α inhibitor-induced paradoxical skin lesions in SAPHO syndrome."

Journal • Ankylosing Spondylitis • Immunology • Musculoskeletal Diseases • Oncology • Pain • Seronegative Spondyloarthropathies • Spondylarthritis

Possible Diclofenac-Related Fulminant Toxic Epidermal Necrolysis: A Case Report. (PubMed, Cureus) - "Though anticonvulsants, sulfonamides, and allopurinol are most frequently associated with TEN, nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac have been involved in very few case reports. Using the Naranjo algorithm for evaluating the causal relationship between a drug therapy and a possible side effect, we obtained a score of 2, which points to a possible side effect, while the re-exposure to febuxostat, etoricoxib, and pregabalin was an alternate pharmacological variable during the course of the adverse event. This case highlights the potential for rapidly progressive and fatal TEN following recent NSAID exposure and underscores the importance of early recognition, prompt withdrawal of suspected medications, and careful causality assessment in patients receiving multiple drugs."

Journal • Acute Kidney Injury • Gout • Hematological Disorders • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology • Steven-Johnson Syndrome • Thrombocytopenia

Effects of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacological Effects of Orally Administered Tramadol: A Randomised Controlled Trial. (PubMed, Basic Clin Pharmacol Toxicol) - "In conclusion, celecoxib modestly inhibited the bioactivation of tramadol, but not etoricoxib. Differences in pharmacological effects were negligible."

Journal • PK/PD data • Pain

AgAIN Study: Better Efficacy of Secukinumab Over Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis with Insights into Sex-Specific Outcomes (EULAR 2026) - P3 | "Concomitant medication for PsA and plaque type psoriasis was similar in both treatment groups for Etoricoxib (SEC: 19.6%; UST 17.5%) and Prednisone (SEC: 3.6%; UST: 1.6%). Within the SEC group, less Celecoxib (1.8%) and Prednisolone (5.4%) were used compared to UST (11.1% and 23.8%, respectively)...Adalimumab was the most frequently used prior TNF-α inhibitor treatment (SEC: 68%; UST: 70%)...Overall, these results support SEC as an effective therapeutic option for TNFi-experienced PsA patients and underscore the value of comprehensive outcome assessments across musculoskeletal, skin, and patient-reported measures. These data may inform treatment selection to address unmet needs in routine care for patients previously exposed to TNFi."

Clinical • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

The Effect of Multimodal Analgesia on Postoperative Pain Management: A Study From a Pain-Free Hospital Project. (PubMed, Pain Physician) - "Our study demonstrates that implementing a structured perioperative protocol emphasizing preemptive analgesia and multimodal analgesia resulted in pain management effects, including decreased incidences of severe postoperative pain and reduced analgesic opioid consumption."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Pain

Etoricoxib-Induced Fixed Drug Eruption: A Case Series and Assessment of Tolerance to Alternative NSAIDs (EAACI 2026) - "Provocations were carried out with aspirin in 4 patients (50%), ibuprofen in 2 (25%), naproxen in 1 (12.5%), and meloxicam in 1 (12.5%)...Notably, most patients exhibited a multifocal pattern. OP testing with alternative NSAIDs was well tolerated in all evaluated cases."

Clinical • Allergy • Immunology

Etoricoxib Associated Fixed Drug Eruption: A Case Series from a Tertiary Allergy and Clinical Immunology Centre, United Arab Emirates (EAACI 2026) - "One patient reported a similar reaction to ibuprofen, while another tolerated alternative NSAIDs, simialr pattern has been described previously 1 . Etoricoxib is an important and potentially under-recognised cause of FDE, with presentations ranging from localised to extensive disease. Careful drug history and recognition of characteristic recurrence are essential. Selective avoidance and identification of safe alternative analgesics are key to management."

Clinical • Late-breaking abstract • Allergy • Immunology

Late-onset toxic epidermal necrolysis (TEN) associated with nivolumab: attention to possible cofactors (EAACI 2026) - "Cofactors such as iodinated contrast media and NSAIDs such as etoricoxib can precipitate severe exacerbations. Allergy testing and discontinuation of the causative drug are key to preventing potentially fatal recurrences."

IO biomarker • Late-breaking abstract • Immunology

Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing (EAACI 2026) - "Based on these findings, a graded oral drug provocation test with celecoxib was performed and was well tolerated, with no adverse reactions during the challenge or subsequent therapeutic use, confirming a safe alternative treatment. Conclusion This case highlights the diagnostic and clinical value of patch testing in fixed drug eruption, enabling accurate identification of the culprit drug and guiding safe therapeutic alternatives."

Ankylosing Spondylitis • Dermatitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies

Etoricoxib-Induced Fixed Drug Eruption: A Case Series and Assessment of Tolerance to Alternative NSAIDs (EAACI 2026) - "Provocations were carried out with aspirin in 4 patients (50%), ibuprofen in 2 (25%), naproxen in 1 (12.5%), and meloxicam in 1 (12.5%)...Notably, most patients exhibited a multifocal pattern. OP testing with alternative NSAIDs was well tolerated in all evaluated cases."

Clinical • Allergy • Immunology